Codexis

ECO Platform Partnerships Will Transform Pharma Manufacturing

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

29 Mar 25

Updated

01 May 25

Views

n/a

AnalystConsensusTarget's Fair Value

n/a

-71.2%

-7.1%

-71.2%

-7.1%

You can edit this narrative until May 12 5:59 AM. Then, changes will post as Updates.

Author's Valuation

US$7.0883.3% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates5

Shared on 01 May 25

Fair value Increased 53%

Shared on 24 Apr 25

Fair value Decreased 24%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 13%

AnalystConsensusTarget has decreased revenue growth from 33.4% to 23.1%, increased future PE multiple from 54.4x to 63.7x and decreased shares outstanding growth rate from 0.2% to 0.1%.

AnalystConsensusTarget Fair Value

US$7.08

83.3% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

23.64%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.17%

Calculation

US$19.65m

Earnings '28

55.55x

PE Ratio '28

US$1.09b

Market Cap '28

US$1.09b

Market Cap '28

123.20m

No. shares '28

US$8.86

Share Price '28

US$8.86 Share Price '28

Discounted to 2025 @ 7.74% p.a.

US$7.08

Fair Value '25